^
Association details:
| Biomarker: | LRP1B mutation |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Imbruvica (ibrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation
Published date:
12/06/2020
Excerpt:
...141 patients were enrolled and treated with daily oral ibrutinib (420 mg or 560 mg) plus intravenous nivolumab...In DLBCL, WES analyses demonstrated that mutations in...KLHL14 (30.0% vs. 0%; p = 0.046), and LRP1B (30.0% vs. 6.2%; p = 0.264) were more frequent in responders...
DOI:
10.1016/j.tranon.2020.100977
Trial ID:
